Ascentage Pharma Group International
AAPG · Price history
Price at last available close
$14.99
+$0.10 (+0.67%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Ascentage Pharma Group International
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation.
How they make money
Ascentage Pharma is a global, commercial-stage biopharmaceutical company that generates revenue primarily through the discovery, development, and commercialization of novel, small-molecule therapies for cancer. The company monetizes its intellectual property by selling its proprietary oncology products and through licensing and collaboration agreements for its clinical-stage pipeline.
Products & services
The company's primary commercial products include Olverembatinib, a tyrosine kinase inhibitor for chronic myeloid leukemia, and Lisaftoclax, a BCL-2 inhibitor for hematologic malignancies.
Brands & revenue mix
A tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Separate brand revenue is not available in this research.Source
A BCL-2 inhibitor for hematologic malignancies launched in China in 2025.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of drug substances and drug products.Source
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 63.7% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Quarterly EPS turned negative at -1.30 versus 0.33 a year earlier.
Separate recurring operating losses from noncash or one-time charges, and check cash flow rather than interpreting negative EPS as a cash-outflow amount.
Quarterly net income turned from a profit to a loss versus the same quarter last year.
Identify the causes in the interim report and distinguish operating cash use from accounting charges. Prior profitability is not a guarantee of recovery.
Diluted weighted-average shares increased 26.1% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
23
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
37
Poor
Financial Strength
35
Business Quality / Moat
42
Management
0
Growth Quality
100
Risk / Durability
8
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
44
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
58/100
Building Historical Record
Model Score 58/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently moderate.
- •Recent buyback activity is present
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for AAPG
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can AAPG maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can AAPG fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does AAPG's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for AAPG to reach sustainable profitability?
- •What future growth or profitability would be needed to justify AAPG's current valuation?
Essential Investment Snapshot
Wall Street Score
23
Opportunity Score
44
Market Cap
$1.39B
P/E Ratio
-3.3
EPS
$-4.46
52-Week High
$35.46
52-Week Low
$14.46
Beta
0.66
Analyst Target
$40.00
Shares Outstanding
89.0M
Total Revenue
$153.0M
Total Debt
$313.3M
Dividend
No current dividend
Liquidation Value / Share
$0.95
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for AAPG
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Elevated debt risk
Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on AAPG.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary drug discovery platform.
- +Commercial-stage product portfolio.
Potential downside factors
- −Debt risk (elevated): Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Dependence on clinical trial success and regulatory approvals.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
23
Oct 1, 2026
Change
Unchanged
Current Score
23
Oct 23, 2026
Category Changes
AAPG score was unchanged.
Projected Score
Projected Score
27
Projected Change
+3.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 3.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$14.98
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $153.0M | $83.5M | $146.6M | $33.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $22.8M | $19.7M | $4.3M | $4.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $130.3M | $63.8M | $142.3M | $28.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $343.6M | $162.0M | $141.6M | $105.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $161.3M | $78.1M | $57.3M | $56.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $504.9M | $240.1M | $197.6M | $159.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$348.7M | -$163.4M | -$35.5M | -$111.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$374.6M | -$176.3M | -$55.3M | -$130.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $7.8M | $7.9M | $9.6M | $14.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$385.3M | -$179.8M | -$59.1M | -$139.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $4.6M | $1.0M | $1.6M | -$1.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$389.8M | -$180.8M | -$60.6M | -$138.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-4.46 | $-2.03 | $-0.80 | $-7.85 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 93.31M | 89.03M | 75.52M | 17.64M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 93.31M | 89.03M | 75.52M | 17.64M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$44.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.30
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+22.1%
Cash Change
+14.1%
Margin Change
-17.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels. Pressure indicators included debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 27.9%. EPS increased 25.4%. Cash increased 14.1%. Total debt increased 22.1%. Net income margin declined by 17.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
Ascentage Pharma Stock Could More Than Double: Analyst
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 4% – Should You Buy?
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Rumor Mill · AAPG
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial